The estimated Net Worth of Mark Erlander is at least $731 mil dollars as of 25 November 2022. Dr Erlander owns over 10,000 units of Cardiff Oncology stock worth over $56,551 and over the last 9 years he sold CRDF stock worth over $0. In addition, he makes $674,323 as CEO & Director at Cardiff Oncology.
Sign up
Dr Erlander CRDF stock SEC Form 4 insiders trading
Dr has made over 19 trades of the Cardiff Oncology stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of CRDF stock worth $14,300 on 25 November 2022.
The largest trade he's ever made was exercising 90,000 units of Cardiff Oncology stock on 30 January 2018 worth over $207,900. On average, Dr trades about 9,025 units every 68 days since 2016. As of 25 November 2022 he still owns at least 24,481 units of Cardiff Oncology stock.
You can see the complete history of Dr Erlander stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Mark Erlander biography
Dr. Mark Erlander is the CEO & Director at Cardiff Oncology.
What is the salary of Dr Erlander?
As the CEO & Director of Cardiff Oncology, the total compensation of Dr Erlander at Cardiff Oncology is $674,323. There are no executives at Cardiff Oncology getting paid more.
How old is Dr Erlander?
Dr Erlander is 61, he's been the CEO & Director of Cardiff Oncology since . There are no older and 1 younger executives at Cardiff Oncology.
What's Dr Erlander's mailing address?
Mark's mailing address filed with the SEC is C/O CARDIFF ONCOLOGY, INC., 11055 FLINTKOTE AVE, SAN DIEGO, CA, 92121.
Insiders trading at Cardiff Oncology
Over the last 5 years, insiders at Cardiff Oncology have traded over $0 worth of Cardiff Oncology stock and bought 966,810 units worth $1,962,891 . The most active insiders traders include Gary W Pace, Gary S Jacob y Mark Erlander. On average, Cardiff Oncology executives and independent directors trade stock every 41 days with the average trade being worth of $74,449. The most recent stock trade was executed by Gary W Pace on 19 December 2023, trading 30,000 units of CRDF stock currently worth $41,100.
What does Cardiff Oncology do?
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics;CY140, an inhibitor of PLK1, PLK2 and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials;TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012.Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
What does Cardiff Oncology's logo look like?
Complete history of Dr Erlander stock trades at Cardiff Oncology
Cardiff Oncology executives and stock owners
Cardiff Oncology executives and other stock owners filed with the SEC include:
-
Dr. Mark Erlander,
CEO & Director -
Charles Monahan R.Ph.,
Sr. VP of Regulatory Affairs -
Dr. Tod Smeal Ph.D.,
Chief Scientific Officer? -
Dr. Katherine L. Ruffner M.D.,
Chief Medical Officer -
James E. Levine,
Chief Financial Officer -
Elizabeth Anderson,
VP of Fin. & Admin. -
Vicki Kelemen,
Exec. VP & COO -
Brigitte Lindsay,
VP of Fin. -
Lale White,
Director -
James O Armitage,
Director -
Gary W Pace,
Director -
Thomas Phd Adams,
-
Rodney S Markin,
Director -
Vicki Kelemen,
Exec. VP and COO -
Mark Erlander,
Chief Executive Officer -
Renee P Tannenbaum,
Director -
Gary S Jacob,
-
James E. Levine,
Chief Financial Officer -
Katherine L Ruffner,
Chief Medical Officer -
John P Brancaccio,
-
Tod Smeal,
Chief Scientific Officer -
Fairooz Kabbinavar,
Chief Medical Officer